<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03268733</url>
  </required_header>
  <id_info>
    <org_study_id>Folic acid in PCOS</org_study_id>
    <nct_id>NCT03268733</nct_id>
  </id_info>
  <brief_title>The Effects of Folic Acid on Sudanese Women With Polycystic Ovary Syndrome</brief_title>
  <acronym>FolicacidPCOS</acronym>
  <official_title>The Clinical and Biochemical Effects of Folic Acid on Sudanese Women With Polycystic Ovary Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Khartoum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Awad, Mohamed Ibrahim, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duria abdulwahab Elrrayes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Khartoum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open clinical trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients with PCOS will be recruited to receive folic acid (45 patients) and equal number
      will receive no folic acid
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pregnancy rates</measure>
    <time_frame>3 months</time_frame>
    <description>Pregnancy rates will be compared in the treatment group and control group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ovulatory pattern improvements</measure>
    <time_frame>3 months</time_frame>
    <description>Ovulatory pattern will be assessed based on the history of the PCOS patients, the patients whom were having baseline oligomenorrhea or amenorrhea will be re-assessed for resuming regular cycles defined as periods lasting 22 - 35 days. this pattern improvement will be compared in the treatment group and control group using questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical signs of hyperandrogenemia</measure>
    <time_frame>3 months</time_frame>
    <description>Hirsutism will be used as a sign of hyperandrogenemia, Patients will be provided with modified Ferriman -Gallwey (mFG) images to self-rate hair growth in each of the 9 body areas (upper lip, chin, chest, upper and lower back, upper and lower abdomen, thighs, and upper arms). For each site, a score on a scale of 0 to 4 was recorded. A total score of 8 or greater is defined as clinical evidence of hirsutism; scores from 8 to 15 are considered mild hirsutism; scores from16 to 25 are considered moderate; and scores from 26 to 36 are considered severe hirsutism. The baseline and after 3 months hirsutism compared in the treatment group and control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma level of testosterone</measure>
    <time_frame>3 months</time_frame>
    <description>Plasma level of testosterone will be compared in the treatment group and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of insulin</measure>
    <time_frame>3 months</time_frame>
    <description>Plasma level of insulin will be compared in the treatment group and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of follicle-stimulating hormone (FSH)</measure>
    <time_frame>3 months</time_frame>
    <description>Plasma level of follicle-stimulating hormone will be compared in the treatment group and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of luteinizing hormone (LH)</measure>
    <time_frame>3 months</time_frame>
    <description>Plasma level of luteinizing hormone will be compared in the treatment group and control group</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lipid profile</measure>
    <time_frame>3 months</time_frame>
    <description>Lipid profile will be compared in the treatment group and control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma level of random glucose</measure>
    <time_frame>3 months</time_frame>
    <description>Plasma level of random glucose will be compared in the treatment group and control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma level of folate</measure>
    <time_frame>3 months</time_frame>
    <description>Plasma level of folate will be compared in the treatment group and control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma level of homocysteine (Hcy)</measure>
    <time_frame>3 months</time_frame>
    <description>Plasma level of homocysteine (Hcy) will be compared in the treatment group and control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma level of hemoglobin (Hb)</measure>
    <time_frame>3 months</time_frame>
    <description>Plasma level of hemoglobin (Hb) will be compared in the treatment group and control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma level of C-reactive protein (CRP)</measure>
    <time_frame>3 months</time_frame>
    <description>Plasma level of C-reactive protein (CRP) will be compared in the treatment group and control group</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 PCOS patients will receive 5 mg folic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>45 PCOS patients will receive no folic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>Tablet 5 mg</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who will visit this centre suffering from PCOS-related subfertility will be
             invited to be enrolled to this study if met the Rotterdam criteria for the diagnosis
             of PCOS

        Exclusion Criteria:

          -  The patients whom will be excluded from the study are those comorbid with
             hyperprolactinemia, congenital adrenal hyperplasia, diabetes mellitus, significant
             cardiovascular problems, thyroid dysfunctions, unresolved medical conditions, or using
             medications suspected to affect reproductive or metabolic functions within two months
             of the study entry.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female patients suffering from PCOS-related subfertility</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Hassan Alnazeer</last_name>
    <role>Study Chair</role>
    <affiliation>University of Khartoum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammed Hassan Alnazeer</last_name>
    <phone>00249912907268</phone>
    <email>mhmd_nazir83@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saad Abul ella fertility Centre</name>
      <address>
        <city>Khartoum</city>
        <zip>11111</zip>
        <country>Sudan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed ibrahim Awad</last_name>
      <phone>00249900904060</phone>
      <email>awad22mohd@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Khartoum</investigator_affiliation>
    <investigator_full_name>Mohammed Hassan Alnazeer</investigator_full_name>
    <investigator_title>Clinical Pharmacist</investigator_title>
  </responsible_party>
  <keyword>Folic acid</keyword>
  <keyword>PCOS</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>still undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

